Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant–dependent lung carcinomas-Reference-Cited by-同舟云学术

Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant–dependent lung carcinomas

Published:2007-02-01 Issue:2 Volume:117 Page:346-352
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Li Danan,Ji Hongbin,Zaghlul Sara,McNamara Kate,Liang Mei-Chih,Shimamura Takeshi,Kubo Shigeto,Takahashi Masaya,Chirieac Lucian R.,Padera Robert F.,Scott Andrew M.,Jungbluth Achim A.,Cavenee Webster K.,Old Lloyd J.,Demetri George D.,Wong Kwok-Kin

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference30 articles.

1. EGFR Targeted Therapy: View from Biological Standpoint

2. ERBB receptors and cancer: the complexity of targeted inhibitors

3. ErbB-targeted therapeutic approaches in human cancer

4. The EGF receptor family as targets for cancer therapy

5. Overview of Monoclonal Antibodies and Small Molecules Targeting the Epidermal Growth Factor Receptor Pathway in Colorectal Cancer

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hierarchically Structured Molecularly Imprinted Nanotransducers for Truncated HER2-Targeted Photodynamic Therapy of Therapeutic Antibody-Resistant Breast Cancer;ACS Nano;2023-05-15

2. A novel EGFR inhibitor suppresses survivin expression and tumor growth in human gefitinib-resistant EGFR-wild type and -T790M non-small cell lung cancer;Biochemical Pharmacology;2021-11

3. Parthenolide inhibits the growth of non-small cell lung cancer by targeting epidermal growth factor receptor;Cancer Cell International;2020-11-23

4. Promising Chimeric Antigen Receptors for Non-B-Cell Hematological Malignancies, Pediatric Solid Tumors, and Carcinomas;Chimeric Antigen Receptor T-Cell Therapies for Cancer;2020

5. A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan;Journal of Immunology Research;2019-01-13